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Introduction
Neurometabolic diseases refer to a group of disorders that are characterized by 
a lack or dysfunction of an enzyme or vitamin necessary for a specific chemical 
reaction in the body.
A lack or dysfunction of an enzyme can cause a deficiency of an essential product 
(metabolites) in the brain that leads to specific types of neurometabolic diseases. A 
lack of these essential metabolites may impair normal brain development. Further, 
this lack of essential metabolites can also cause stored materials that may become 
toxic to the brain especially in the developing brains in children.
Abstract
Objective 
Neurometabolic disorders are an important group of diseases that mostly are 
presented in newborns and infants.
Neurological manifestations are the prominent signs and symptoms in this group 
of diseases. Seizures are a common sign and are often refractory to antiepileptic 
drugs in untreated neurometabolic patients.
The onset of symptoms for neurometabolic disorders appears after an interval of 
normal or near normal growth and development.Additionally, affected children 
may fare well until a catabolic crisis occurs.
Patients with neurometabolic disorders during metabolic decompensation have 
severe clinical presentation, which include poor feeding, vomiting, lethargy, 
seizures, and loss of consciousness.
This symptom is often fatal but severe neurological insult and regression in 
neurodevelopmental milestones can result as a prominent sign in patients who 
survived.
Acute symptoms should be immediately treated regardless of the cause. 
A number of patients with neurometabolic disorders respond favorably and, in 
some instances, dramatically respond to treatment.
Early detection and early intervention is invaluable in some patients to prevent 
catabolism and normal or near normal neurodevelopmental milestones.
This paper discusses neurometabolic disorders, approaches to this group of 
diseases (from the view of a pediatric neurologist), clinical and neurological 
manifestations, neuroimaging and electroencephalography findings, early 
detection, and early treatment.
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The toxic material would otherwise be metabolized 
by the specific enzymes. Accumulation of these toxic 
metabolites has harmful effect on brain and lead to loss 
of nerve cells and breakdown of brain white and gray 
matters. 
Neurometabolic diseases are inherited disorders that 
are individually rare but as a group have a significant 
burden.
Defects or mutations in a single gene disrupt structure 
and function of corresponding protein enzyme that lead 
to significant neurometabolic disease. Although children 
may have the same gene mutation but without suffering 
the same neurometabolic problems, some children are 
severely ill at birth and die soon after presentation of 
symptoms while others might be only mildly affected 
and their symptoms present later in life.
The most common presenting signs of inborn errors of 
metabolism are neurological manifestations.
Global neurodevelopmental delay is only the first 
symptoms in many of these progressive disorders.
Signs and Symptoms 
The presenting symptoms for neurometabolic diseases 
are caused by progressive destruction of mental, motor, 
and perceptual functions. The symptoms can appear at 
any age from newborns into adulthood.
In some neurometabolic disorders, the structure of 
brain has abnormally developed before birth (such 
as in Zellweger syndrome), but in other disorders just 
after birth and at the start of feeding, symptoms become 
apparent. The symptoms include seizures, loss of 
consciousness, hypotonia, poor feeding, and respiratory 
distress,among others.
Other neurometabolic disorders present in young infants 
with neurodevelopmental delay. These infants fail to 
progress to normal development and suffer recurrent 
episodes of vomiting, lethargy, and loss of consciousness 
brought on by environmental stresses such as upper 
respiratory tract infections, vaccination, or surgery, 
among others. (1).
An abnormal odor of the body and urine, microcephaly or 
macrocephaly, visual loss and auditory loss, and seizures 
in these patients may lead to further investigations of 
neurometabolic diseases.
After one or two years, children may show regressions in 
skills, i.e. learned motor and mental skills (2). 
Older infants may also show hepatosplenomegaly, 
coarse facies, skeletal abnormalities, and uncontrolled 
seizures. Sometimes parents report abnormalities with 
the hair and skin, especially dermatitis in sun-exposed 
regions.
Children may show an abnormal gait as with ataxia, 
mental decline, abnormal behavior, and sleep disorders. 
Neurological examinations may reveal abnormal tones, 
spasticity, or hypotonicity, and brisk deep tendon 
reflexes.
In addition, children may show visual loss, poor 
attention, speech disturbance, and cerebellar signs.
In adulthood, neurometabolic diseases mainly have 
psychiatric sign and aggressiveness, mood disorders, and 
behavioral disorders are the major sign of neurometabolic 
disorders.
Disorders of Amino acids
Phenylketonuria (PKU)
PKU is caused by phenylalanine hydroxylase deficiency, 
a hepatic enzyme that converts phenylalanine to tyrosine 
(two important aminoacids).
Phenylalanine hydroxylase deficiency causes an 
accumulation of phenylalanine, which is then converted 
to phenyl pyruvic acid and phenyl lactic acid. These 
metabolites are excreted in the urine.
Phenylalanine and their metabolites are neurotoxic and 
untreated patients are typically profoundly mentally 
retarded. 
Children with PKU appear normal at birth and have 
normal neurodevelopmental milestones in early infancy, 
but gradually they show reduced head circumference and 
developmental delays. Children with PKU may have a 
musty odor especially in the urine due to metabolites of 
phenyl lactic acid and phenyl pyruvic acid. Behavioral 
disorders and autistic spectrum disorders are common in 
these children.
Brain Magnetic resonance imaging (MRI) shows 
a high intensity in periventricular white matter 
(dysmyelination). These findings are reversible with a 
restricted diet of phenylalanine.
Abnormal findings in the white matter demonstrate 
restricted diffusion of water which indicates high myelin 
turnovers. 
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The severity of MRI findings (white matter involvement) 
correlate with mean phenylalanine levels in the past 
years and point to phenylalanine levels at the time of 
brain imaging (Figure 1) (3).
Many studies have revealed correlation between 
phenylalanine serum levels and MRI white matter 
involvement in conventional methods and a higher 
sensitivity in Diffusion Weighted Imaiging (DWI).
Karimzadeh et al in the study of “MRI Changes in 30 
patients with phenylketonuria” indicated an assessment 
of mean 1-year phenylalanine levels are the best indicator 
of white matter involvement and are more related with 
MRI scores compared to phenylalanine levels at the time 
of imaging (4). 
This study suggests the use of brain MRIs and evaluation 
of white matter involvement to monitor long-term 
control of phenylalanine levels in PKU cases.
 
Fig 1. Abnormally high signal intensity in white matter 
regions around the anterior and posterior horns of both 
lateral ventricles and brain atrophy in phenylketonuria
In order to prevent neurotoxicity from phenylalanine, 
patients with PKU need a diet that restricts phenylalanine. 
This restricted diet causes normal plasma phenylalanine 
and stops the excretion of phenylpyruvic acid and 
phenyl lactic acid. The selective restrictions of Phe. and 
tyrosine supplementation lead to normal growth and 
neurodevelopment. 
An abnormal EEG that includes generalized paroxysmal 
activity and a generalized slowing are common even in 
patients who have received treatments. 
High serum phenylalanine levels in untreated 
women with PKU can cross the placenta and cause 
Microcephaly(70%), intrauterine growth retardation 
(40%), and congenital heart disease (12%) in the fetus.
Mothers with PKU should be monitored carefully with 
a restricted diet of phenylalanine and the diet should be 
started 3 months before conception. 
Maple Syrup Urine Disease 
At first, Menkes et al described this disease. Maple Syrup 
Urine Disease (MSUD) is caused by a mitochondrial 
branched chain α-ketoacid dehydrogenase deficiency. 
The defect of this enzyme leads to accumulation 
of branched chain amino acids and branched chain 
α-ketoacids.
MSUD has 5 types: classic, intermediate, intermittent, 
thiamine responsive, and dihydrolipoyl dehydrogenase 
deficiency.
The clinical manifestations are different and depend on 
the level of enzyme activity.
In the classic type of MSUD, with severe encephalopathy, 
symptoms start in newborns and early infancy and include 
poor feeding, hypertonia, opisthotonic posturing, failure 
to thrive, respiratory disorders, seizures, and urine that 
smells like maple syrup.
Affected infants may be misdiagnosed with sepsis and 
die from seizures and coma.
Hyponatremia and cerebral edema are common during 
acute metabolic states. Infants who survive ametabolic 
crisis have severe neurodevelopmental delays as well as 
visual and mental deficits. 
A brain MRI is typically abnormal in MSUD patients. 
Magnetic resonance spectroscopy (MRS) shows a peak 
of branched chain amino acids and branched chain 
α-ketoacids resonating at 0.9–1.0 ppm, especially during 
a metabolic crisis (Figure 2).
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Organic-acidemia
Ketotic hyperglycinemia includes propionic-academia, 
methylmalonic-academia, and isovaleric-academia all 
have similar clinical pictures. 
A severe metabolic crisis presents as hyperammonemia, 
severe ketoacidosis, vomiting, poor feeding, lethargy, 
and coma. Undiagnosed children often die in early 
infancy. The clinical presentation depends on 
enzymatic deficiencies. Even in patients with mild 
clinical presentations, in late infancy and childhood the 
metabolic crisis can be fatal. During acute metabolic 
crisis, treatment is limited to catabolism and restricted 
protein intake.
Propionic-acidemia is a congenital neurometabolic 
disorder of organic acid metabolism, which is recessively 
inherited, characterized by a spectrum of clinical, and 
biochemical manifestations. 
This disorder can present with life-threatening 
ketoacidosis, lethargy, failure to thrive, and 
developmental delays.
Karimzadeh et al reported that for 10 patients with 
propionic-acidemia, the first and chief complaint in 
70% of patients were neurological disorders, such as 
developmental delay and seizures. In this study, 70% 
of refractory seizures were controlled with antiepileptic 
drug and L-carnitine (5).
MRIs in patients with organic-academia show a pathology 
of the bilateral basal ganglia and some abnormal 
nonspecific intensity in the periventricular white matter 
(especially during an acute metabolic state). Children 
with severe handicaps and global neurodevelopmental 
delays show severe cerebral atrophy in cranial MRIs 
(Figure 3).
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Fig 3. Abnormal Signal in Bilateral Basal Ganglia and Brain Atrophy in an MRI from a 4-year-old 
boy with propionic-acidemia
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Previous studies, Ozand and Karimzadeh et al, have 
shown that early intervention in propionic-acidemia 
caused partial improvements in the demyelination of 
white matter but basal ganglia involvement did not 
completely resolve (5,6).
Methylmalonic-acidemia, another inborn error of amino 
acid metabolism, presents with neurologic deficits, 
metabolic acidosis, vomiting, lethargy, anorexia, and 
severe ketoacidosis.
Karimzadeh et al indicated that in a study with 20 
patients who have methylmalonic-acidemia, 60% had 
a history of seizures (30% tonic, 20% GTC, and 10% 
infantile spasm); 20% had refractory seizures; all types 
of refractory seizures were controlled after diagnosis and 
treatment of methylmalonic-academia (7).
In this study, MRIs from 50% of patients had brain 
atrophy, 15% had basal ganglia involvement (mostly in 
putamen), 10% had abnormal signal in periventricular 
white matter regions,and 30% had a normal brain MRI 
(7).
Radmanesh et al indicated that 52 patients with 
methylmalonic-academia, their cortical atrophy, and 
ventricular dilation were observed from neuroimaging 
(8).
Biotinidase deficiency is a neurometabolic disorders that 
patients respond to high doses of oral Biotin very well. 
Symptoms include alopecia, skin rash, 
neurodevelopmental delay, and seizures as well as visual 
and hearing impairments. 
A cranial MRI shows abnormal signal intensity in the 
periventricular white matter, which is extensive in some 
patients (Figure 4). 
One study indicated that16 patients with biotinidase 
deficiency showed the following:75% of patients 
had abnormal neuroimaging and of these, 56% had 
generalized brain atrophy and delay myelination. 
Additionally, this study showed seizures and skin 
manifestations were improved after biotin therapy (9).
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Karimzadeh et al study on Glutaricaciduria type 1 and 
with a 5-year follow up of these patients indicated no 
pattern of macrocephaly at birth.However, 25% of these 
patients had a larger head circumference than weight, 
but further follow-ups showed that 50% of these patients 
had macrocephaly (greater than 95%). The 5-year 
follow-up showed that patients with early diagnosis 
had a more favorable clinical response to treatment 
(10). 
In this study, serial neuroimaging were done in seven 
patients and five of them (71%) followed a particular 
pattern indicated by fronto temporal atrophy and a 
widening of the Sylvian sulcus with white matter and 
basal ganglia involvement and subependymal cyst (10).
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Disorders of Carbohydrate Metabolism
Galactosemia is an inborn error of carbohydrate 
metabolism (deficiency of Galactose 1-phosphate uridyl 
transferase) that causes neurologic manifestations 
that include impaired mental development, vomiting, 
cataracts, pseudotumor cerebri, and cerebral edema as 
well as other signs such as hepatomegaly and failure to 
thrive, among others.
Clinical manifestations usually appear after initiation of 
milk feeding and increase in severity in the first days and 
months of life.
Impaired mental development is an important 
manifestation and is more severe in those who are not 
diagnosed as a newborn or in early infancy.It is common 
for untreated patients to be hyperactive and have 
impaired mental development. A relationship between 
mental decline and compliance with dietary restrictions 
was evident in average IQ, especially as regards poorly 
compliant patients who had an IQ below 70.
Mitochondrial disorders
The body’s nucleated cells contain 500–2000 
mitochondria. Some organs such as the brain, heart, 
and skeletal muscles are highly energy dependent. 
Therefore, these organs are vulnerable to defects with 
energy metabolism.
 In the cone cell photoreceptors of the eye, mitochondria 
make up 80% of the intracellular volume meanwhile in 
extraocular muscles like the lateral rectus, mitochondria 
occupies 60% of intracellular volume and 40% for the 
heart muscles.
In the liver, mitochondria are specialized to detoxify 
ammonia in the urea cycle and are required for 
neurotransmitter metabolism.
Mitochondrial encephalomyopathies are genetically, 
biochemically, and clinically heterogeneous group of 
disorders associated with abnormalities of oxidative 
phosphorylation.
There is no absolute gold standard to establish a 
diagnosis of mitochondrial encephalomyopathy. Lethal 
infantile mitochondrial disease is characterized by a 
fulminant neonatal onset (death within 6 months of life) 
cardiomyopathy,and myopathy.
Patients with Sengers syndrome are diagnosed with 
congenital cataracts, hypertrophic cardiomyopathy, 
mitochondrial myopathy, and lactic acidosis.
Another syndrome as Barth syndrome, which is 
diagnosed with left ventricular non compaction (LVNC), 
skeletal myopathy, 3-methylglutaconic aciduria, and 
short stature.
Diagnostic criteria for pediatric mitochondrial disorders 
have been modified from the adult classification system 
known as “The Modified Walker Criteria” (Table1).
The Modified Walker Criteria is useful to assess 
the frequency of major clinical manifestations in a 
population of infants and children with a definite 
diagnosis of mitochondrial disease because the natural 
history of this heterogeneous group of disorders remains 
largely unknown.From this, we are able to gather a large 
group of pediatric patients with a definite diagnosis of 
a mitochondrial disorder and study the clinical histories 
(11, 12).
Neurological manifestations are important signs for 
these disorders. Most neurological manifestations 
include the following: muscle weakness (proximal 
muscle more affected than distal and upper extremities 
are more affected than lower extremities), hypotonia, 
peripheral neuropathy, ataxia, ptosis, ophthalmoplegia, 
bulbar signs, spasticity stroke-like episodes, migraine, 
headaches, tremors, chorea, ballismus, dystonia, seizures 
and myoclonus.
Mitochondrial disorders can present with some 
classic mitochondrial syndromes such as chronic 
progressive external ophthalmoplegia (CPEO),Leber 
hereditary optic neuropathy (LHON), mitochondrial 
encephalopathy, lactic acidosis, and stroke like 
syndromes (MELAS), myoclonic epilepsy with ragged 
red fibers (MERRF), mitochondrial myopathy (MNGIE), 
peripheral neuropathy, gastrointestinal encephalopathy, 
neuropathy, ataxia, retinitis pigmentosa (NARP), and 
Kearns-Sayre syndrome are the most important (13,14).
Mitochondrial DNA depletion syndrome, also known 
as Alpers syndrome, is an autosomal recessive disorder 
characterized by clinical findings of psychomotor 
retardation, intractable seizure, and liver failure. Seizures 
may initially be focal and then generalize tonic clonic 
seizure arethe prominent signs.
Epilepsia partialis continua and convulsive status 
epilepticus are common. The disorder, diagnosed in 
infants and young children, is progressive and often 
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leads to death from hepatic failure or status epilepticus before age 3. 
 
Table 1. Modified Walker Criteria Applied to Children of Mitochondrial Disease 
2 major criteria or 1 major plus 2 minor = Mitochondrial Disorders (11)
Major Criteria Minor Criteria
Clinical
Clinically complete Respiratory chain en-
cephalomyopathy or a mitochondrial cytopathy 
defined as fulfilling all 3 of the following
Symptoms compatible with a Respiratory 
Chain defect
Histology >2% ragged red fibers in skeletal muscle
Smaller numbers of RRF, Sub sarcolemmal 
Accumulation of Mitochondria, or widespread 
electron microscopy abnormalities of 
mitochondria
Enzymology
Cytochrome c oxidase negative fibers or 
residual activity of a RC complex <20% in a 
tissue; <30% in a cell line, or <30% in 2 or more 
tissues 
Antibody-based demonstration of an RC defect
or residual activity of an RC complex 20%–30% 
in a tissue, 30%–40% in a cell line, or 30%–
40%
 in 2 or more tissues 
Functional
Fibroblast ATP synthesis rates >3 SD below 
mean
Fibroblast ATP synthesis rates 2–3 SD below 
mean, or fibroblasts unable to grow in 
galactose media
Molecular
Nuclear or mtDNA mutation of undisputed 
pathogenicity
Nuclear or mtDNA mutation of probable 
pathogenicity
Metabolic
One or more metabolic indicators of impaired 
metabolic function
The clinical manifestations in mitochondrial disorders 
are wide. Conditions are divided into the following 
groups:
Conditions with Nuclear DNA Defects
1. Substrate transport defect
2. Carnitine transporter deficiency
3. Carnitine palmitoyltransferase I deficiency
4. Carnitine–acylcarnitine translocase deficiency
5. Carnitine palmitoyltransferase II
6. Defects of Substrate Utilization
7. Pyruvate carboxylase deficiency, 
8. Pyruvate dehydrogenase complex deficiency 
9. Defects of beta-oxidation
10. Defects of oxidation–phosphorylationcoupling
11. Defects of the Krebs cycle
12.Defects of the respiratory chain
Approach to Neurometabolic Diseases from a Pediatric Neurological Point of View 
13. Defects of protein importation
14. Defects of the lipid milieu of the inner mitochondrial 
membrane
15.Defects of mitochondrial motility, fusion, and fission




3.Point mutations affecting synthetic genes
4.Acquired conditions associated with mitochondrial 
dysfunction
In mitochondrial disorders, any organ can be involved. 
Peroxisomal disorders
Peroxisomal disorders are a group of heterogeneous 
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Zellweger spectrum disorders include three peroxisome 
biogenesis disorders as follows: Zellweger syndrome, 
neonatal adrenoleukodystrophy, (NALD), and infantile 
Refsum disease.
Although all have a similar molecular basis, Zellweger 
syndrome is the most severe of the three disorders.
Infants with Zellweger syndrome show elevated very 
long chain fatty acids in their blood plasma. Cultured skin 
fibroblasts obtained from patients show elevated very 
long chain fatty acids, phytanic acid,and plasminogen.
Neurological manifestations defined as neuronal 
migrational defects, craniofacial abnormalities, eye 
defects, chondrodysplasia punctata, and hepatomegaly.
Craniofacial abnormalities include high forehead, 
epicanthal fold, large fontanel, and midface hypoplasia 
(17). 
Neuronal Ceroid-lipofuscinosis
Neuronal Ceroid-lipofuscinosis (NCL) is a group of 
neurodegenerative diseases that represent a common 
inherited neurodegenerative disease in childhood. 
NCL has different types as follows: infantile, late 
infantile, juvenile, and adult types with juvenile type 
the most common. Various types of NCL are inherited 
fromautosomal recessive inheritance. 
Several mutations have identified that deletion as the 
CLN3 gene as the most common mutation for the most 
common type (Juvenile type or Batten disease). The 
CLN1 mutation may give rise to the infantile or juvenile 
forms (18, 19). 
Electroretinograms (ERGs) from these patients show 
electronegative electroretinogram with a severe loss of 
b waves and the histopathologic studies have revealed 
reduced all cell numbers from all retinal layers.
Seizures are a common sign that is often refractory to 
anti-epileptic drugs and electroencephalograms show 
that these patients’ have generalized atypical spike and 
slow wave complexes.
There is no current specific treatment for neuronal 
ceroid-lipofuscinosis.Therefore, the management of 
patients focuses on the control of seizures. 
Storage disease
Lysosomal storage disorders
This group of storage diseases is a clinically 
neurometabolic diseases that show the dysfunction of 
peroxisome.
Adrenoleukodystrophy
X-linked adrenoleukodystrophy(X-linked ALD) is an 
inherited, recessive, neurodegenerative disease that 
affects the white matter of the brain and the adrenal 
gland.
The disorder is caused by mutations in the ABCD1gene 
and leads to a defect in the peroxisomal transport 
membrane protein (ABCD1),which impairs peroxisomal 
b-oxidation, and then,results in the accumulation of 
very long-chain fatty acids. It is a progressive disorder 
characterized by Addison’s disease, dementia, and 
neurological deterioration (15,16).
There are several distinct clinical phenotypes that range 
from cerebral forms, adrenomyeloneuropathy (AMN) to 
asymptomatic persons or isolated adrenal insufficiency 
without CNS involvement, i.e. Addison’s disease only. 
Childhood cerebral ALD and adult 
adrenomyeloneuropathy are common clinical 
phenotypes.
Cerebral X-ALD can be presented as childhood, 
adolescent, and adult forms.
Affected boys with the childhood type usually present 
before 10 years of age (typically between 4–8 years of 
age) characterized as a rapidly progressive disorder with 
ataxia, spasticity, deafness, visual deficits, personality 
changes, and seizures. The less common adolescent 
form after 10 years of age demonstrates a similar course. 
Cerebral X-ALD is frequently associated with Addison’s 
disease, but primary adrenal insufficiency may coexist 
or develop after neurological disturbances. 
Typical MR findings in patients with cerebral ALD 
are well documented and consist of bilateral white 
matter abnormalities. Typically, they occur initially in 
the posterior cerebral regions and progress to parietal, 
temporal, and then frontal lobes sequentially. Such a 
pattern is found in approximately 80% of cases; therefore, 
MRIs strongly suggest the diagnosis of X-ALD
Zellweger syndrome
Zellweger or cerebrohepatorenal syndrome is a rare 
neurometabolic disorder characterized by areduction or 
absence of functional peroxisomes in cells.
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heterogeneous group of neurometabolic disorders that 
neurological manifestations are prominent clinical 
findings.
Lysosome facilitates the degradation of various products 
of cellular turn over that are mainly derived from 
lysosomes through endocytosis.
Alternative pathways for substrate entry into lysosomes 
are phagocytosis.
Mucopolysaccharidoses comes from abnormalities in 
the turnover of keratin sulfate, heparin, and dermatan 
sulfate; Gaucher disease is due to glucocerebrosidase 
deficiencies; the accumulation of its substrate 
glycosphingolipid glucosylceramide; and Fabry 
disease results from alpha-galactosyl sphingolipids 
oligosaccharides.
Other lysosomal disorders are cystinosis and sialic 
acid storage disorders that involve a dysfunction of 
the intracellular membrane transport that mediates 
movement of the products outside the lysosome for the 
final step of excretion.
GM1 gangliosidosis is the results of a beta-galactosidase 
deficiency and the accumulation of ceramides caused by 
an acid ceramidase deficiency that causes Farber disease.
GM2 gangliosidosis as Tay-Sachs disease (an alpha 
subunit of beta hexosaminidase deficiency); Sandhoff 
disease (a beta subunit of beta-hexosaminidase 
deficiency); and the GM2 AB variant are other types of 
lysosomal storage diseases.
The complex lipid of gangliosides is found 
predominantly in gray matter in the brain. Classic forms 
of gangliosidoses present in early and late infancy and 
are usually fatal during these periods.
In the early infantile form of GM1,gangliosidoses 
dysmorphic features may present at birth and 
often hepatosplenomegaly is noted. The bone 
deformity (dysostosis multiplex) is similar to 
mucopolysaccharidosis. Macular cherry red spot (CRS) 
is found in about 50% of patients and hypotonia, feeding 
difficulties, and failure to thrive may be evident in the 
first weeks and months of life. Affected infants develop 
spasticity, tonic spasms, and pyramidal signs; and infants 
who survive beyond 12 months exhibit decerebrate 
rigidity.
CRS is also a hallmark of Tay-Sachs disease. In the 
classic form of Tay-Sachs disease, affected infants have 
psychomotor deterioration and hyperacusis together with 
axial hypotonia. The size of head increases markedly 
and patients become spastic in the second year of life.
Karimzadeh et al indicated that, for18 patients with GM2-
Gangliosidosis (9 patients with Sandhoff and 9 with Tay 
Sachs disease), CRS was reported in 88% of patients. 
Also in this study, 7patients had macrocephaly, 3 had 
microcephaly, and 8 had a normal head circumference. 
Therefore, macrocephaly was not considered significant 
in this assessment (20).
The late onset form of the disease can manifest in 
childhood and adolescence with cerebellar ataxia, 
and dysarthria due to cerebellar atrophy. Tonic clonic 
seizures and psychiatric disturbances are present and 
may be the initial problems. Peripheral neuropathy has 
been described and has been considered for late onset 
Tay-Sachs disease. 
Sphingomyelinase deficiency causes an accumulation of 
sphingomyelin in Niemann-Pike type A, Arylsulfatase 
deficiency leads to accumulation of sulfatides in 
metachromatic leukodystrophy and galactocerebrosidase 
deficiency causes Krabbe disease.
There is wide heterogeneity in the clinical presentation 
of these diseases. Clinical manifestation may be evident 
prenatally or at any time from birth to adulthood. For 
example, Gausher disease and Fabry may not be 
associated with prominent symptoms during infancy and 
childhood. 
Type 1 Gausher disease as the most common lysosomal 
storage disease presents with hematologic and visceral 
findings. Type2 presents with the acute neuropathic 
form during infancy that leads to spasticity, dysphagia, 
and death before 2–3 years of age.
Type 3 Gausher disease that manifests before 2 years 
of age shows chronic neurological problems including 
seizures, ataxia, and extrapyramidal rigidity.
Oculomotor apraxia (especially horizontal saccadic 
eye movement failure) is a characteristic finding in 
neuropathic Gausher disease. Supra nuclear horizontal 
gaze palsy may be the single neurological problem in 
Gausher disease type 3. 
There are at least three disorders as follows: Fabry, Danon, 
and Hunter syndrome (MPS II) that are transmitted as 
X-linked traits but most lysosomal storage diseases are 
transmitted in autosomal recessive inheritance.
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Pinto et al reported a combined prevalence of about 1 in 
5000–8000 for lysosomal storage diseases. 
Some defined ethnic groups such as the Ashkenazi 
population has a high frequency of some lysosomal 
storage diseases like Tay-Sachs, Gausher, and Niemann-
Pick type A.
Enzyme replacement therapy for Gausher disease, 
Fabry, Pompe (Glycogen storage disease type II), 
Hurler-Scheie (MPS I H/S), Hunter, and Maroteaux-
Lamy disease (MPS VI), is available.
Niemann-Pick type C disease is a rare progressive 
neurodegenerative disorder with autosomal recessive 
inheritance.The underlying biochemical defect is 
an impaired lipid metabolism, which is caused by 
pathological mutations of either the NPC1 (95%) or the 
NPC2 (5%) gene.
Niemann-Pick disease type C (NPC) has wide clinical 
heterogeneity and can present during the neonatal period, 
infancy, childhood, or adulthood. Pre- or peri-natal 
and early-infantile diseases are usually detected from 
prolonged neonatal jaundice and hepatosplenomegaly.
In addition, very young patients often display central 
hypotonia and developmental delays (21,22,23).
Late infancy and juvenile Niemann-Pick disease type 
C can present as dystonia, dysarthria, or dysphagia, 
and,usually presents with ataxia and supranuclear gaze 
palsy. Patients from these two groups often display 
gelastic cataplexy, epilepsy, and cognitive impairment 
that can manifest as learning disabilities (24).
Substrate reduction therapy with miglustat has been 
reported, which can be a stabilizer
Neurological manifestations in patients with Niemann-
Pick disease type C; 
Study of Karimzadeh and her colleagues on 21 Iranian 
NPC Patients supported previous findings demonstrating 
stabilization of neurological disease with miglustat in 
children diagnosed in the early stages of the disease. 
Similar to published previous reports, these patients 
did not show improvement in systemic manifestations. 
Despite the other studies about gastrointestinal problems 
(diarrhea and anorexia) during Miglustat therapy that 
they had to discontinue treatment due to adverse effects, 
Iranian patients tolerated well the Miglustat (25). 
Urea cycle disease
Urea cycle enzyme disorders include carbamylphosphate 
synthetase deficiency,arginosuccinic aciduria, ornithine 
transcarbamylase deficiency, citrullinemia, arginase 
deficiency, and N-acetylglutamate synthetase deficiency.
Deficiencies of enzymes in Urea cycle disorders lead to 
hyperammonemia and present classically with a loss of 
consciousness and coma.
The most common type of presentations is ornithine 
transcarbamylase deficiency. The inheritance of this 
disorder is X-linked and presents in males. 
In Urea, cycle disease hyper-ammonia is not associated 
with acidosis as it is associated with acidosis in organic-
acidemia. Patients with Urea cycle disease, are more 
likely to have respiratory alkalosis. Orotic aciduria 
is found in patients with ornithine transcarbamylase 
deficiency. Orotic aciduria also is found in citrullinemia 
and argininemia. In patients without orotic aciduria, the 
expected diagnosis is carbamyl phosphate synthetize 
deficiency or N-acetyl glutamate synthetize deficiency. 
In the acute hyperammonemia all intake of protein or 
other sources of nitrogen should be stopped. Glucose 
is used for the promotion of hyper-anabolism, water, 
and electrolytes are provided intravenously. Arginine 
to keep urea cycle supplied and intravenous sodium 
benzoate and sodium phenyl acetate are used for 
excretion of waste nitrogen.
Hemodialysis is often required in acutely 
hyperammonemic newborns.
Follow-ups of children who treated for pharmacologic 
therapy showed up to a 90% survival rate but 80% 
of these patients had significant developmental 
disabilities.
In addition, a significant relationship was found 
in these patients between the duration of neonatal 
hyperammonemic coma, the level of mental decline, 
and IQ.
Neuroimaging findings in neurometabolic 
disorders
MRIs are an important neuroimaging tool for evaluating 
neurodevelopmental disorders.
Routine MRIs are usually the first step in the evaluation 
of neurodevelopmental and neurometabolic disorders.
MRIs are the choice for neuro-image studies of 
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brain structural abnormality, normal and abnormal 
myelination, and functioning.
Today, functional MRIs have an important value for 
motor and learning abilitiesof the brain. 
MRS is a reliable and noninvasive method to study the 
brain biochemistry in neurometabolic disorders.
MRS shows the regional metabolic abnormality as 
an etiologic factor of the disease.In addition, we can 
use MRS to evaluate the rapeutic management and 
progression of neurometabolic diseases.
MRS for studying of neurometabolic 
disorders
The analysis of metabolic peaks in MRS in combination 
of clinical finding (History & physical examination), 
metabolic study, and biochemical data are a good 
method for confirmation of neurometabolic disease.
MRS is a good predictor for response to treatment, 
disease severity, and outcome of disorders.
Proton MR Spectroscopy (PMRS) is a diagnostic test 
for specific neurometabolic disorders, for example 
peak of N- acetylaspartate (NAA) in Canavan disease 
due to aspartoacylase deficiency, peak of Phe. in 
phenylketonuria (PKU) due to phenylalanine hydroxylase 
deficiencies, peak of leucine, isoleucine,and valine in 
MSUD disease due to Debranche enzyme deficiency 
and also is diagnostic for Urea cycle disorders.
MRS in phenylketonuria shows a peak of phenylalanine 
at 7.37 ppm. The size of the peak is useful for monitoring 
of serum phenylalanine and monitoring of treatment.
MRS in Maple Syrup Urine disease shows macromolecule 
peaks typically seen at 0.9 ppm to represent branched 
chain amino acids and branched chain alpha ketoacids.
MRS reveals the peak of a lactate doublet at 1.33 ppm 
in mitochondrial disorders. MRS in mitochondrial 
encephalopathy with lactic acidosis (MELAS) and 
mitochondrial with ragged red fiber (MERRF)shows 
lactate rising.In Kerns-Sayre syndrome, MRS for 
affected regions in the brain show increased lactate and 
reduced NAA (26).
Additionally,proton MR spectrum (TE=288) in Leigh 
disease shows a large lactate doublet at 1.33 ppm in 
the affected regions (basal ganglia, brain stem, and 
white matter). In these patients, NAA peaks in Proton 
MR Spectrum (TE=144) are markedly reduced in size. 
Lactate peaks are inverted at intermediate echo times.
Approach to Neurometabolic Diseases from a Pediatric Neurological Point of View 
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In some studies, MRS revealed, even in carriers of amino 
acid disorders, slightly higher levels of brain amino 
acids were detected. Weglage and coworkers measured 
levels of brain phenylalanine by MRS and found that in 
carriers a PKU level of phenylalanine was higher than 
for non-carriers. 
During episodes of acute metabolic catabolism in organic-
academia and Maple syrup disease accumulations of 
Lactate and ketoacids have been detected.
In a creatine deficiency, H proton MRS, demonstrates 
severely decreased or absent for creatine/
phosphocreatine peak. In addition, MRS can be used 
for monitoring treatment with creatine monohydrate in 
these patients.
On the other hand, H-MRS is used for early detection 
of asymptomatic high-risk children for neurometabolic 
disease.
MRS can be used for monitoring the response to 
treatment.
In some studies, MRS has been used for monitoring the 
response of dichloroacetate and other therapeutic agents 
in mitochondrial group diseases.
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 Fig 6. Cranial MRI and MRS in a patient with glutaric aciduria type I and Axial MRI shows an 
abnormal signal in bilateral basal ganglia with bilateral prominent sylvian fissures
Diffusion tensor imaging in neurometabolic 
disorders
Diffusion tensor imaging has been used for the evaluation 
of white matter disorders.
This modality is a noninvasive evaluation for diagnosis 
of neurodegenerative disorders involv ng predominantly 
white matter and possible leukodystrophies. 
In X-linked adrenoleukodystrophy, white matter 
demyelination typically begins in posterior white matter 
(occipital region) and then extends anteriorly. 
In addition, diffusion tensor imaging has been used 
for the evaluation of water diffusion in mitochondrial 
disorders.
Diffusion tensor imaging is a helpful modality for 
study of neurometabolic disorders involving white 
matter structures such as phenylketonuria and ornithine 
transcarbamylase deficiency.
Epilepsy and EEG patterns for neurometabolic 
diseases
Although, Neurometabolic disorders are not a frequent 
cause of epil psy, ep lepsy is a frequent symptom of 
neurometabolic disease. Epilepsy in this group of disease 
has different types of seizures and EEG patterns.
Epilepsy in neurometabolic disorders can be a prominent 
symptom especially in newborns and early infants.
In these patients, epilepsy can cause neurodevelopmental 
regression in motor, mental, and speech milestones. It is 
often referred to as epileptic encephalopathy.
The type of epilepsy depends on the age rather than 
the type of neurometabolic disorders.The common 
types of epilepsy in these patients are early myoclonic 
13Iran J Child Neurol. 2015 Winter Vol 9 No 1
Approach to Neurometabolic Diseases from a Pediatric Neurological Point of View 
encephalopathy in newborns, early myoclonic epilepsy, 
infantile spasm, and west syndrome in infancy; 
generalized tonic clonic seizures in late infantile and 
childhood period; and unexplained status epilepticus is 
common in these patients (27,28).
The history of these patients also shows consanguinity 
marriage in parents, positive family history of similar 
cases, neurodevelopmental delays, psychomotor 
regression, and abnormal neurological examination.
EEGs are abnormal in most of neurometabolic epileptic 
patients.
Burst suppression patterns in EEG are often due to 
neurometabolic diseases, especially in non-ketotic 
hyperglycinemia, urea cycle disorders, organic aciduria, 
sulfite oxidase deficiency, and biotinidase deficiency in 
newborn and early infants (Figure 7).
EEGs in West syndrome show a hypsarrhythmia 
pattern. It is defined as a chaotic pattern and irregularity 
throughout tracing (Figure 8).
In childhood, neurometabolic-causing epilepsy presents 
as progressive myoclonic epilepsy.
The main cause of progressive myoclonic epilepsy 
(PME) is neuronal ceroid-lipofuscinosis (NCL), other 
causes of PME are MERRF (myoclonic epilepsy ragged 
ref fiber), sialidosis, Lafora disease, Gaucher disease 
type III, GM2 gangliosidosis, and Unverricht-Lundborg 
disease (Figure 9).
Rhythmic delta waves associated with paroxysmal 
response during photic stimulation in the EEG are highly 
suggestive of PME.
Epilepsy of neurometabolic disease is often resistance 
to antiepileptic drugs. When an early infant shows 
refractory seizures, neurometabolic disease should be 
considered.
In some of neurometabolic disease with refractory 
to antiepileptic drugs, specific treatment of basic 
neurometabolic diseases in these patients such as 
supplementation cofactors, diet therapy, and/or specific 
treatment of deficient metabolites can help control 
seizures.
For example, refractory seizures in biotinidase deficiency 
have a good response to high dose of biotin. 
Some antiepileptic drugs may worsen neurological 
and clinical conditions of patients with neurometabolic 
disorders such as valproic acid in mitochondrial disease; 
urea cycle disease; and organic-academia cause seizure 
worsening, loss of consciousness, and abnormal liver 
functioning tests.
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Fig 8. Hypsarrhythmia patterns with mixed asynchronous slow waves and spike waves in an 8.5-month-old infant 
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